Why the study?
Heart failure and atrial fibrillation frequently coexist with growing prevalence, but the effect of clinical course and management across different ejection fractions on outcomes required evaluation.
What are the predictors of unfavorable outcomes in patients with concurrent heart failure and atrial fibrillation across different ejection fraction categories?
Cohort (n=1,003)
Yes
What are the predictors of unfavorable outcomes in patients with concurrent heart failure and atrial fibrillation across different ejection fraction categories?
In patients with concurrent HF and AF, different ejection fraction categories exhibit distinct prognostic patterns, with HFrEF driving cardiovascular mortality and HFmrEF driving HF hospitalizations.
Answers are grounded in this paper and cite their sources.
HFpEF associated with lower composite risk in HF-AF; leaves open EF-specific prognostic patterns for prospective validation.
Heart failure (HF) and atrial fibrillation (AF) are the most common cardiovascular conditions in clinical practice and frequently coexist. The number of patients with HF and AF is increasing every year. Aim . To analyze the effect of clinical course and management of HF and AF on the outcomes. Material and methods . The data of 1,003 patients from the first Russian register of patients with HF and AF (RIF-CHF) were analyzed. The endpoints included hospitalization due to decompensated HF, cardiovascular mortality, thromboembolic events, and major bleeding. Predictors of unfavorable outcomes were analyzed separately for patients with HF with preserved ejection fraction (AF+HFpEF), mid-range ejection fraction (AF+HFmrEF), and reduced ejection fraction (AF+HFrEF). Results . Among all patients with HF, 39% had HFpEF, 15% — HFmrEF, and 46% — HFrEF. A total of 57,2% of patients were rehospitalized due to decompensated HF within one year. Hospitalization risk was the highest for HFmrEF patients (66%, p=0,017). Reduced ejection fraction was associated with the increased risk of cardiovascular mortality (15,5% vs 5,4% in other groups, p<0,001) but not ischemic stroke (2,4% vs 3%, p=0,776). Patients with HFpEF had lower risk to achieve the composite endpoint (stroke+MI+cardiovascular death) as compared to patients with HFmrEF and HFrEF (12,7% vs 22% and 25,5%, p<0,001). Regression logistic analysis revealed that factors such as demographic characteristics, disease severity, and selected therapy had different effects on the risk of unfavorable outcomes depending on ejection fraction group. Conclusion. Each group of patients with different ejection fractions is characterized by its own pattern of factors associated with unfavorable outcomes. The demographic and clinical characteristics of patients with mid-range ejection fraction demonstrate that these patients need to be studied as a separate cohort.
No takes yet. Share an insight, caveat, or question.
Жиров et al. (2021) conducted a cohort in Heart failure and atrial fibrillation (n=1,003). Heart failure with preserved ejection fraction (HFpEF) vs. Heart failure with mid-range (HFmrEF) and reduced ejection fraction (HFrEF) was evaluated on Composite of stroke, myocardial infarction, and cardiovascular death (p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: